Human Immunodeficiency Virus Type 1 Market Size to Reach US$ 39.8 Billion by 2034, Impelled by Advancements in Early Detection

Human Immunodeficiency Virus Type 1 Market Outlook 2024-2034:

The human immunodeficiency virus type 1 market size reached a value of US$ 24.4 Billion in 2023. Looking forward, the market is expected to reach US$ 39.8 Billion by 2034, exhibiting a growth rate (CAGR) of 4.56% during 2024-2034. The market is driven by the emerging popularity of therapeutic human immunodeficiency virus (HIV) vaccines, which aim to stimulate an immune response against the pathogen, thereby controlling the infection and slowing down the disease progression. Additionally, the development of targeted therapies and innovative treatments is further propelling the market growth.

Advances in Early Detection and Diagnostic Technologies: Driving the Human Immunodeficiency Virus Type 1 Market 

Advances in early detection and diagnostic technologies are significantly driving the human immunodeficiency virus type 1 (HIV-1) market by improving the speed, accuracy, and accessibility of diagnosis. Early diagnosis of HIV-1 is crucial for initiating timely antiretroviral therapy (ART), preventing the progression of acquired immunodeficiency syndrome (AIDS), and reducing transmission. The availability of more efficient diagnostic tools has not only improved patient outcomes but also expanded the HIV-1 treatment market. One of the most notable advancements is the development of rapid point-of-care (POC) tests. These tests, including rapid HIV antibody tests and nucleic acid tests (NATs), enable the detection of HIV within minutes to hours, offering greater convenience and accessibility, especially in resource-limited settings. This increased accessibility to testing drives earlier detection and linkage to care, enhancing the effectiveness of treatment interventions. Molecular diagnostics, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), have further revolutionized the landscape by allowing for the detection of HIV-1 at very low viral loads, including during the acute infection stage when the virus is often undetectable with traditional antibody-based tests. These methods also enable genetic resistance testing, allowing clinicians to tailor ART regimens based on the patient’s specific viral strain, which is essential for optimizing treatment outcomes and preventing resistance. Moreover, advancements in home-based testing kits and mobile health technologies have improved convenience, enabling individuals to monitor their HIV status in private and seek care sooner. The rise in these testing technologies has driven greater patient awareness, fostering earlier diagnosis, better treatment adherence, and improved public health outcomes.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of novel therapies and pharmacological treatments is a key driver in the expansion of the human immunodeficiency virus type 1 market, providing patients with more effective, convenient, and personalized treatment options. One of the major contributions to the market is the development of long-acting injectable ART. Drugs such as cabotegravir and rilpivirine, delivered via monthly or even quarterly injections, are designed to replace daily oral regimens. These long-acting formulations improve patient adherence, particularly among those who face challenges with daily pill-taking or have difficulty maintaining strict medication schedules. This not only improves treatment outcomes but also enhances the overall quality of life for individuals living with HIV-1. Furthermore, the emergence of combination therapies that combine multiple agents into a single tablet has simplified treatment regimens. These fixed-dose combinations reduce pill burden, minimize drug-drug interactions, and improve patient compliance, making it easier for individuals to manage their condition effectively. Some of the newer combinations also include next-generation integrase inhibitors and pharmacokinetic enhancers, which have shown improved efficacy and reduced toxicity profiles compared to earlier treatments. In addition to this, immunotherapies and gene-editing technologies, such as CRISPR-Cas9, are being investigated as potential solutions for eradicating HIV-1 or achieving long-term remission. Therapeutic vaccines and monoclonal antibodies are also being explored to enhance immune responses and suppress viral replication without the need for lifelong ART. As these therapies advance through clinical trials, they hold the promise of improving patient outcomes, reducing treatment costs, and expanding the market further.

Marketed Therapies in Human Immunodeficiency Virus Type 1 Market

Ziagen (Abacavir Sulfate): GlaxoSmithKline 

Ziagen (Abacavir Sulfate) is a carbocyclic synthetic nucleoside analog that acts as an antiviral to treat HIV. Cellular enzymes convert abacavir into the active metabolite carbovir triphosphate, which is an analog of deoxyguanosine-5'-triphosphate (dGTP). Carbovir triphosphate suppresses HIV-1 reverse transcriptase (RT) activity by competing with its natural substrate, dGTP, and incorporating it into viral DNA. Viral DNA growth is inhibited because the integrated nucleotide lacks a 3'-OH group, which is required to create the 5′ to 3′ phosphodiester linkage required for DNA chain elongation.

Videx (Didanosine): Bristol-Myers Squibb

Videx (didanosine) is a synthetic purine nucleoside that inhibits the human immunodeficiency virus. Didanosine is a synthetic nucleoside analog of the naturally occurring nucleoside deoxyadenosine in which the 3'-hydroxyl group is replaced by hydrogen. Cellular enzymes convert didanosine into the active metabolite, dideoxyadenosine 5'-triphosphate. Dideoxyadenosine 5'-triphosphate inhibits the activity of HIV-1 RT both by competing with the natural substrate, deoxyadenosine 5'-triphosphate, and by its incorporation into viral DNA causing termination of viral DNA chain elongation.

Emtriva (Emtricitabine): Gilead Sciences

Emtriva (Emtricitabine) is utilized in combination with other drugs for the treatment of HIV-1 infections in adults and children. Emtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated by cellular enzymes to produce emtricitabine 5'-triphosphate. Emtricitabine 5'-triphosphate inhibits HIV-1 reverse transcriptase by competing with the natural substrate deoxycytidine 5'-triphosphate and incorporating it into nascent viral DNA, leading to chain termination.

Epivir (Lamivudine): ViiV Healthcare 

Epivir (Lamivudine) is prescribed in combination with other antiretrovirals for the treatment of HIV infection. Lamivudine is a synthetic nucleoside analog that is phosphorylated intracellularly to form the active 5'-triphosphate metabolite lamivudine triphosphate (L-TP). This nucleoside analog is integrated into viral DNA by HIV reverse transcriptase and HBV polymerase, causing DNA chain termination.

Viread (Tenofovir Disoproxil Fumarate): Gilead Sciences

Viread (Tenofovir Disoproxil Fumarate) is used in combination with other antiretroviral medications to treat HIV-1 infection in adults and children patients aged 2 years or older weighing at least 10 kg. Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Tenofovir disoproxil fumarate requires diester hydrolysis to convert to tenofovir, which is then phosphorylated by cellular enzymes to generate tenofovir diphosphate (TFVDP), an obligate chain terminator. Tenofovir diphosphate inhibits HIV-1 RT and HBV RT by competing with the natural substrate deoxyadenosine 5'-triphosphate and causing DNA chain termination.

Emerging Therapies in Human Immunodeficiency Virus Type 1 Market

Cabotegravir: ViiV Healthcare 

Cabotegravir is an integrase strand transfer inhibitor (INSTI) developed by ViiV Healthcare to treat HIV-1 in virologically suppressed individuals. It is approved as a long-acting formulation for use in conjunction with a rilpivirine long-acting formulation in the United States, the European Union, and other nations. Cabotegravir blocks HIV replication by preventing viral DNA from integrating into the genetic material of human immune cells (T-cells). This stage is critical in the HIV replication cycle and is also responsible for establishing chronic infection.

Vesatolimod: Gilead Sciences

Vesatolimod is an antiviral medication developed by Gilead Sciences that acts as a powerful and selective agonist of Toll-like receptor 7 (TLR7), an immune system regulator. It is an orally administered small molecule that functions by binding to and activating TLR7, a pattern-recognition receptor (PRR) found largely on plasmacytoid dendritic cells (pDCs) and B cells.

Zinlirvimab+Teropavimab: Gilead Sciences

Zinlirvimab+Teropavimab are monoclonal antibodies that treat HIV-1, targeting different areas of the HIV-1 envelope glycoprotein gp120. Teropavimab works by targeting the CD4-binding site of the HIV-1 envelope glycoprotein gp120, whereas zinlirvimab targets the HIV-1 envelope V3 glycan supersite. These interactions mechanistically block HIV-1 virions' initial entrance into the host CD4+ cell, a critical phase in HIV infection.

Lenacapavir: Gilead Sciences

Lenacapavir is a first-in-class capsid inhibitor being studied for HIV-1 treatment. The HIV capsid protein, located in the HIV-1 gene's group-specific antigen (gag) region, has a variety of roles in HIV replication. Lenacapavir interacts with the viral capsid protein, which inhibits nuclear transport, virus assembly and release, and capsid assembly in new virions. Lenacapavir's prolonged release from the injection site, along with its low systemic clearance (in vivo), makes it a promising option for long-acting HIV therapy. Furthermore, lenacapavir had synergistic effects and remained effective against resistant HIV-1 strains in vitro when paired with other antiretroviral treatments.

B/F/TAF: Gilead Sciences

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen recommended for HIV-1 treatment. Bictegravir is an integrase inhibitor, which prevents viral DNA integration into the host genome, whereas Emtricitabine and Tenofovir Alafenamide are nucleoside reverse transcriptase inhibitors (NRTIs), which hinder viral replication by inhibiting reverse transcription. Together, they efficiently inhibit HIV-1 replication.

Detailed list of emerging therapies in Human Immunodeficiency Virus Type 1 is provided in the final report.

Leading Companies in the Human Immunodeficiency Virus Type 1 Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global human immunodeficiency virus type 1 market, several leading companies are at the forefront of developing integrated platforms to enhance the management of human immunodeficiency virus type 1. Some of the major players include GlaxoSmithKline, ViiV Healthcare, and Gilead Sciences. These companies are driving innovation in the human immunodeficiency virus type 1 market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for the illness.

​In July 2024, ViiV Healthcare announced the 48-week results from PASO DOBLE (GeSIDA 11720 study), the largest head-to-head, phase IV randomized clinical trial (RCT) examining the 2-drug regimen DOVATO (dolutegravir/lamivudine [DTG/[3TC]) compared to the 3-drug regimen BIKTARVY (bictegravir/emtricitabine]/tenofovir alafenamide fumarate [BIC/FTC/TAF]) for the treatment of HIV-1 individuals who are virologically suppressed and who could benefit from treatment optimization.

Key Players in Human Immunodeficiency Virus Type 1 Market:

The key players in the Human Immunodeficiency Virus Type 1 market who are in different phases of developing different therapies are GlaxoSmithKline, Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, and Others.

Regional Analysis:

The major markets for human immunodeficiency virus type 1 include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for human immunodeficiency virus type 1 while also representing the biggest market for its treatment. This can be attributed to the growing adoption of pre-exposure prophylaxis, which is contributing to a decline in new HIV infections and increased demand for prevention medications.

Moreover, ongoing innovations in ART have dramatically improved the management of HIV-1, shifting the focus from merely controlling the virus to achieving undetectable viral loads and improving the long-term health of individuals living with HIV. Long-acting injectable treatments, such as cabotegravir and rilpivirine, offer a breakthrough by reducing the need for daily pills, improving patient adherence, and enhancing treatment convenience.

Besides this, the focus on preventive care and ongoing research into therapeutic vaccines and gene-editing technologies hold promise for a future where HIV-1 could be managed more effectively or even eradicated, further expanding market opportunities​.

Recent Developments in Human Immunodeficiency Virus Type 1 Market:

• In April 2024, Gilead Sciences presented the first comprehensive review of the full results of its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is investigating the use of lenacapavir, the company's injectable HIV-1 capsid inhibitor, for HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people. The newly provided results include data on lenacapavir adherence and pharmacokinetics among study participants.
• In October 2023, ViiV Healthcare announced that the National Medical Products Administration (NMPA) of China had approved Vocabria (cabotegravir injection) in combination with Janssen Pharmaceutical Companies' Johnson & Johnson's Rekambys (rilpivirine long-acting injection) for the treatment of HIV-1 infection.
• In February 2023, Gilead Sciences announced data evaluating lenacapavir in combination with broadly neutralizing antibodies (bNAbs) teropavimab and zinlirvimab as a potential long-acting treatment regimen with twice-yearly dosing. Results from the Phase 1b clinical trial demonstrated the investigational combination was generally well tolerated with high efficacy in select virologically suppressed participants living with HIV.

Key information covered in the report.

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the human immunodeficiency virus type 1 market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the human immunodeficiency virus type 1 market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report offers a comprehensive analysis of current human immunodeficiency virus type 1 marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800